|
1
|
Birt DF, Hendrich S and Wang W: Dietary
agents in cancer prevention: flavonoids and isoflavonoids.
Pharmacol Ther. 90:157–177. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Benavente-García O and Castillo J: Update
on uses and properties of citrus flavonoids: new findings in
anticancer, cardiovascular, and anti-inflammatory activity. J Agric
Food Chem. 56:6185–6205. 2008.PubMed/NCBI
|
|
3
|
Arango D, Morohashi K, Yilmaz A, Kuramochi
K, Parihar A, Brahimaj B, Grotewold E and Doseff AI: Molecular
basis for the action of a dietary flavonoid revealed by the
comprehensive identification of apigenin human targets. Proc Natl
Acad Sci USA. 110:e2153–e2162. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Oishi M, Iizumi Y, Taniguchi T, Goi W,
Miki T and Sakai T: Apigenin sensitizes prostate cancer cells to
Apo2L/TRAIL by targeting adenine nucleotide translocase-2. PLoS
One. 8:e559222013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pham H, Chen M, Takahashi H, King J, Reber
HA, Hines OJ, Pandol S and Eibl G: Apigenin inhibits NNK-induced
focal adhesion kinase activation in pancreatic cancer cells.
Pancreas. 41:1306–1315. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim HK, Cheon BS, Kim YH, Kim SY and Kim
HP: Effects of naturally occurring flavonoids on nitric oxide
production in the macrophage cell line RAW 264.7 and their
structure-activity relationships. Biochem Pharmacol. 58:759–765.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Raso GM, Meli R, Di Carlo G, Pacilio M and
Di Carlo R: Inhibition of inducible nitric oxide synthase and
cyclooxygenase-2 expression by flavonoids in macrophage J774A.1.
Life Sci. 68:921–931. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lindenmeyer F, Li H, Menashi S, Soria C
and Lu H: Apigenin acts on the tumor cell invasion process and
regulates protease production. Nutr Cancer. 39:139–147. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
He J, Xu Q, Wang M, Li C, Qian X, Shi Z,
Liu LZ and Jiang BH: Oral administration of apigenin inhibits
metastasis through AKT/P70S6K1/MMP-9 pathway in orthotopic ovarian
tumor model. Int J Mol Sci. 13:7271–7282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Feng X, Zhou Q, Liu C and Tao ML: Drug
screening study using glioma stem-like cells. Mol Med Rep.
6:1117–1120. 2012.PubMed/NCBI
|
|
11
|
Litchfield DW: Protein kinase CK2:
structure, regulation and role in cellular decisions of life and
death. Biochem J. 369:1–15. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Trembley JH, Wang G, Unger G, Slaton J and
Ahmed K: Protein kinase CK2 in health and disease: CK2: a key
player in cancer biology. Cell Mol Life Sci. 66:1858–1867. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ahmad KA, Wang G, Unger G, Slaton J and
Ahmed K: Protein kinase CK2 - a key suppressor of apoptosis. Adv
Enzyme Regul. 48:179–187. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Piazza FA, Ruzzene M, Gurrieri C, Montini
B, Bonanni L, Chioetto G, Di Maira G, Barbon F, Cabrelle A,
Zambello R, Adami F, Trentin L, Pinna LA and Semenzato G: Multiple
myeloma cell survival relies on high activity of protein kinase
CK2. Blood. 108:1698–1707. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Solares AM, Santana A, Baladrón I,
Valenzuela C, González CA, Díaz A, Castillo D, Ramos T, Gómez R,
Alonso DF, Herrera L, Sigman H, Perea SE, Acevedo BE and
López-Saura P: Safety and preliminary efficacy data of a novel
casein kinase 2 (CK2) peptide inhibitor administered
intralesionally at four dose levels in patients with cervical
malignancies. BMC Cancer. 9:1462009. View Article : Google Scholar
|
|
16
|
Perea SE, Baladron I, Garcia Y, Perera Y,
Lopez A, Soriano JL, Batista N, Palau A, Hernández I, Farina H,
Garcia I, Gonzalez L, Gil J, Rodriguez A, Solares M, Santana A,
Cruz M, Lopez M, Valenzuela C, Reyes O, López-Saura PA, González
CA, Diaz A, Castellanos L, Sanchez A, Betancourt L, Besada V,
González LJ, Garay H, Gómez R, Gómez DE, Alonso DF, Perrin P,
Renualt JY, Sigman H, Herrera L and Acevedo B: CIGB-300, a
synthetic peptide-based drug that targets the CK2 phosphoaceptor
domain. Translational and clinical research. Mol Cell Biochem.
356:45–50. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang S, Long H, Yang YL, Wang Y, Hsieh D,
Li W, Au A, Stoppler HJ, Xu Z, Jablons DM and You L: Inhibition of
CK2α down-regulates Notch1 signalling in lung cancer cells. J Cell
Mol Med. 17:854–862. 2013.
|
|
18
|
Zhang S, Wang Y, Mao JH, Hsieh D, Kim IJ,
Hu LM, Xu Z, Long H, Jablons DM and You L: Inhibition of CK2α
down-regulates Hedgehog/Gli signaling leading to a reduction of a
stem-like side population in human lung cancer cells. PLoS One.
7:e389962012.
|
|
19
|
Ren KQ, Cao XZ, Liu ZH, Guo H, Quan MF,
Liu F, Jiang L, Xiang HL, Deng XY and Cao JG:
8-bromo-5-hydroxy-7-methoxychrysin targeting for inhibition of the
properties of liver cancer stem cells by modulation of Twist
signaling. Int J Oncol. 43:1719–1729. 2013.PubMed/NCBI
|
|
20
|
Zhao M, Ma J, Zhu HY, Zhang XH, Du ZY, Xu
YJ and Yu XD: Apigenin inhibits proliferation and induces apoptosis
in human multiple myeloma cells through targeting the trinity of
CK2, Cdc37 and Hsp90. Mol Cancer. 10:1042011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Feliciano A, Castellvi J, Artero-Castro A,
Leal JA, Romagosa C, Hernández-Losa J, Peg V, Fabra A, Vidal F,
Kondoh HY, Cajal S and Lleonart ME: miR-125b acts as a tumor
suppressor in breast tumorigenesis via its novel direct targets
ENPEP, CK2-α, CCNJ and MEGF9. PLoS One. 8:e762472013.PubMed/NCBI
|
